About us



BIOCOZ GLOBAL is a life science and technology company led by Dr. Mihm (Harvard), the chairman of WHO Melanoma, and Dr. Sinskey (MIT), the first world-class life science professor to hold a patent for medical hyaluronic acid.

For 15 years, the research and development of BIOCOZ GLOBAL have been conducted by Dr. Mihm and Dr. Skinket.
As a result, we developed SPM, a bio-active material.
With the innovative technology patented in the US and Korea, we help you in caring for your skin in a healthy way.

  • Martin C. Mihm Jr., MD
    Dr. Martin C. Mihm Jr., MD., is the Director of Melanoma Program at the Department of Dermatology, Brigham and Women’s Hospital, Associate Director at the Center for Melanoma Oncology, Dana-Farber/Brigham and Women’s Cancer Center, and Professor of Pathology and Dermatology at Harvard Medical School. Dr. Mihm served 20 years as co-director of the Melanoma Pathology Program, World Health Organization and formed the dermatopathology fellowship program at Massachusetts General/Harvard Medical School, one of the first training programs in the specialty which was adopted by Harvard, securing dermatopathology’s place in medicine. Dr. Martin C. Mihm Jr., has been a member of BIOCOZ GLOBAL’s medical advisory board since 2016.
  • Dr. Anthony J. Sinskey
    Dr. Sinskey has been serving on the board since 2015. He is a professor of Microbiology and Engineering Systems at the Massachusetts Institute of Technology (MIT). He also holds positions as co-director of the Malaysia-MIT Biotechnology Partnership Program and as the Faculty Director of the MIT Center for Biomedical Innovation. Dr. Sinskey is well known in the biopharmaceutical industry and has been a scientific co-founder of several biotechnology companies, including Genzyme Corporation, Natural Pharmaceuticals, Metabolix, and Merrimack Pharmaceuticals. He received his Sc.D. in Microbiology and Food Science from the MIT.
  • Chanwha Kim Ph.D.
    Dr. Kim has been serving on the board since 2011. He brings almost thirty years of experience in biotechnology to BIOCOZ GLOBAL. Dr. Kim has been a professor of biotechnology since 1995, and a chief technology officer of the Institute of Life Science and Biotechnology at Korea University since 2005. Prior to his career at the university, Dr. Kim was Director at XGen Corp, Principal Research Engineer at 3M Co., Technical Advisor at Genzyme Corp. and Senior Researcher at ATC Diagnostics Inc. Dr. Kim received his Ph.D. in biotechnology from the MIT.

About SPM

  • SPM is BIOCOZ GLOBAL's original substance.

    SPM is a unique ingredient developed by combining biomaterials at an optimal ratio to care for your skin in a healthy way. By nurturing the skin's natural strength, SPM restores its health from a more fundamental aspect, rather than offering a temporary improvement.

  • The difference that SPM makes

    SPM helps skin rejuvenate. It is an important ingredient that strengthens the skin’s barrier by generating a natural moisturizing factor, a key ingredient in moisturizing your skin. Unlike products offering temporary skin improvement, SPM helps the skin strengthen itself by increasing the density of the skin barrier.

Our History

  • 2020
    • Development of product lines (TBA)
    • SKIN ACTUALLY water essence cosmetic
      - Patent registration for SPM™ technology (USA)
  • 2019
    • Research and Development to prepare for consumer cosmetic product lines
    • Establishment of BIOCOZ GLOBAL Research and Development Center (Korea)
  • 2018
    • SPM™ clinical trial testing producing positive results
      - Supervision by Dr. Ju Hee Lee at Severance Hospital
      - Dermatology Clinical testing for product preparation
    • BIOCOZ GLOBAL, INC. establishment of US branch corporation
  • 2017
    • Commencement of SPM™ clinical trials
      - Supervision by Dr. Ju Hee Lee at Severance Hospital
    • Certificate supporting the safety and efficacy of SPM™
      - Dr. Martin C. Mihm Jr., MD (Harvard Medical School)
    • Patent registration for SPM™ (Republic of Korea)
  • 2016
    • Commencement of in-vivo studies
      - Lead: Dr. Martin C. Mihm Jr., MD (Harvard Medical School)
    • Appointment set for Head of BIOCOZ GLOBAL Medical Advisory Board
      Dr. Martin C. Mihm Jr., MD
  • 2015
    • Validation of in-vitro study results
      - Lead by Dr. Anthony J. Sinskey, Ph.D (Massachusetts Institute of Technology
    • Appointment set as Head of BIOCOZ GLOBAL Scientific Advisory Board
      - Dr. Anthony J. Sinskey, Ph.D (Massachusetts Institute of Technology)
    • Completion of SPM™ formula
      - Dr. Chanhwa Kim, Ph.D (Korea University)/li>
  • 2011
    • Establishment of Singapore corporate headquarters, BIOCOZ GLOBAL Pte. Ltd.
    • Establishment of South Korea subsidiary, BIOCOZ GLOBAL Korea Corp.
    • Development of bioactive composition prototype
    • Initiation of cell activating material studies
      - Dr. Chanhwa Kim, Ph.D (Korea University)/li>
  • 2006
    • Initiation of cell growth activating material studies
      - Lead by Dr. Phan Toan Thang, MD, Ph.D (National University Singapore)